Viracta Therapeutics (VIRX) Competitors $0.0098 0.00 (0.00%) As of 07/25/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VIRX vs. SHPH, TNFA, SCNI, ATXI, CDT, PBM, SLRX, ASLN, BPTH, and EVFMShould you be buying Viracta Therapeutics stock or one of its competitors? The main competitors of Viracta Therapeutics include Shuttle Pharmaceuticals (SHPH), TNF Pharmaceuticals (TNFA), Scinai Immunotherapeutics (SCNI), Avenue Therapeutics (ATXI), Conduit Pharmaceuticals (CDT), Psyence Biomedical (PBM), Salarius Pharmaceuticals (SLRX), ASLAN Pharmaceuticals (ASLN), Bio-Path (BPTH), and Evofem Biosciences (EVFM). These companies are all part of the "pharmaceutical products" industry. Viracta Therapeutics vs. Its Competitors Shuttle Pharmaceuticals TNF Pharmaceuticals Scinai Immunotherapeutics Avenue Therapeutics Conduit Pharmaceuticals Psyence Biomedical Salarius Pharmaceuticals ASLAN Pharmaceuticals Bio-Path Evofem Biosciences Viracta Therapeutics (NASDAQ:VIRX) and Shuttle Pharmaceuticals (NASDAQ:SHPH) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, media sentiment, dividends, profitability, valuation and risk. Do insiders & institutionals believe in VIRX or SHPH? 31.4% of Viracta Therapeutics shares are held by institutional investors. Comparatively, 4.6% of Shuttle Pharmaceuticals shares are held by institutional investors. 10.7% of Viracta Therapeutics shares are held by insiders. Comparatively, 12.6% of Shuttle Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media refer more to VIRX or SHPH? In the previous week, Shuttle Pharmaceuticals' average media sentiment score of 0.00 beat Viracta Therapeutics' score of -1.00 indicating that Shuttle Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Viracta Therapeutics Negative Shuttle Pharmaceuticals Neutral Is VIRX or SHPH more profitable? Shuttle Pharmaceuticals' return on equity of -1,203.10% beat Viracta Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Viracta TherapeuticsN/A -1,899.61% -114.21% Shuttle Pharmaceuticals N/A -1,203.10%-370.42% Which has stronger earnings & valuation, VIRX or SHPH? Shuttle Pharmaceuticals is trading at a lower price-to-earnings ratio than Viracta Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioViracta TherapeuticsN/AN/A-$51.06M-$1.10-0.01Shuttle PharmaceuticalsN/AN/A-$9.15M-$4.15-0.82 Do analysts recommend VIRX or SHPH? Viracta Therapeutics currently has a consensus target price of $1.75, indicating a potential upside of 17,793.66%. Given Viracta Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Viracta Therapeutics is more favorable than Shuttle Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Viracta Therapeutics 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33Shuttle Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk & volatility, VIRX or SHPH? Viracta Therapeutics has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500. Comparatively, Shuttle Pharmaceuticals has a beta of -1.08, suggesting that its stock price is 208% less volatile than the S&P 500. SummaryViracta Therapeutics beats Shuttle Pharmaceuticals on 8 of the 12 factors compared between the two stocks. Get Viracta Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VIRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VIRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VIRX vs. The Competition Export to ExcelMetricViracta TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$389K$792.54M$5.45B$9.68BDividend YieldN/A4.84%3.99%4.14%P/E Ratio-0.011.3130.1125.01Price / SalesN/A25.14379.5578.79Price / CashN/A19.5635.9458.58Price / Book0.036.558.135.68Net Income-$51.06M-$4.07M$3.26B$265.68M7 Day PerformanceN/A0.30%1.15%2.51%1 Month PerformanceN/A5.04%2.82%1.88%1 Year PerformanceN/A24.76%28.41%24.00% Viracta Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VIRXViracta Therapeutics1.6339 of 5 stars$0.01flat$1.75+17,793.7%N/A$389KN/A-0.0120Negative NewsUpcoming EarningsShort Interest ↑SHPHShuttle Pharmaceuticals0.8123 of 5 stars$3.63+3.7%N/AN/A$1.54MN/A-0.875Negative NewsGap DownTNFATNF PharmaceuticalsN/A$0.11+5.7%N/AN/A$1.52MN/A-0.026Gap UpSCNIScinai Immunotherapeutics1.2276 of 5 stars$1.51+2.7%N/A-57.0%$1.47M$660K-0.1620Gap DownATXIAvenue Therapeutics2.3588 of 5 stars$0.46+1.1%N/A-85.9%$1.46MN/A0.034CDTConduit Pharmaceuticals0.318 of 5 stars$1.88+4.4%N/A-99.2%$1.44MN/A0.003Upcoming EarningsGap UpPBMPsyence Biomedical1.4888 of 5 stars$4.54+92.4%N/A-98.7%$1.34MN/A0.00N/AGap UpHigh Trading VolumeSLRXSalarius Pharmaceuticals0.2234 of 5 stars$0.61-3.2%N/A-76.4%$1.34MN/A-0.1320Gap UpASLNASLAN PharmaceuticalsN/A$0.60flatN/AN/A$1.23M$12M-0.0330BPTHBio-Path0.5525 of 5 stars$0.14-4.9%N/A-90.3%$1.20MN/A0.0010Negative NewsUpcoming EarningsGap DownEVFMEvofem Biosciences0.8945 of 5 stars$0.01+1.1%N/A-7.1%$1.08M$11.39M-0.01120Negative News Related Companies and Tools Related Companies SHPH Alternatives TNFA Alternatives SCNI Alternatives ATXI Alternatives CDT Alternatives PBM Alternatives SLRX Alternatives ASLN Alternatives BPTH Alternatives EVFM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VIRX) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | SponsoredShocked one of my clients with thisTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viracta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viracta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
